# LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

> **NCT00550277** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 20 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** LBH589

## Key facts

- **NCT ID:** NCT00550277
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550277, "LBH589 Treatment for Refractory Clear Cell Renal Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00550277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*